Hester Biosciences Ltd

Hester Biosciences Ltd announced upgrades to its credit ratings from multiple agencies, reflecting information regarding an upgrade in credit rating. CARE Ratings upgraded Long-term Bank Facilities, Long-term / Short-term Bank Facilities, and Short-term Bank Facilities, with ratings of BBB; Stable, BBB+; Stable, BBB; Stable/ A3 +, BBB+; Stable/ A2, and A3 + and A2 respectively, while also upgrading Long Term Bank Facilities from CARE BBB; Stable to CARE BBB+; Stable with a reduced sanctioned amount from 66.25 to 48.45, and Long Term / Short Term Bank Facilities from CARE BBB; Stable / CARE A3+ to CARE BBB+; Stable / CARE A2, alongside upgrading Short Term Bank Facilities from CARE A3+ to CARE A2; CARE Ratings Ltd. also noted a review with the status of "ISSUER NOT COOPERATING" for certain Bank Facilities, and indicated potential annual surveillance/review, along with monitoring of bank facilities, while CareEdge Ratings indicated that ratings reflect opinions as on the date of the rating, and N/A agencies provided no rating data.

Net profit of Hester Biosciences rose 489.90% to Rs 96.98 crore in the quarter ended June 2026 as against Rs 16.44 crore during the previous quarter ended June 2025. Sales declined 8.17% to Rs 77.24 crore in the quarter ended June 2026 as against Rs 84.11 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales77.2484.11 -8 OPM %29.4927.12 - PBDT23.3824.37 -4 PBT16.3320.19 -19 NP96.9816.44 490 Powered by Capital Market - Live

Hester Biosciences reported standalone revenue of Rs 634.90 million for the quarter ended June 30, 2026, a 14% increase compared to Rs 524.69 million in the corresponding quarter of the previous year, while standalone profit increased by 88%. Consolidated revenue decreased to Rs 772.44 million compared to Rs 841.05 million in the prior year, but consolidated profit rose significantly by 459% due to an exceptional gain of Rs 853.49 million from an amendment to a Gates Foundation loan for Hester Africa, which reduced the outstanding loan from USD 12.0 million to USD 5.0 million.

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Shardul Securities Ltd, BF Utilities Ltd, BCL Industries Ltd and Indian Hume Pipe Company Ltd are among the other gainers in the BSE's 'B' group today, 13 July 2026.Hester Biosciences Ltd surged 20.00% to Rs 2531.25 at 13-Jul-2026 EOD IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 21183 shares were traded on the counter so far as against the average daily volumes of 859 shares in the past one month. Shardul Securities Ltd spiked 19.99% to Rs 40.46. The stock was the second biggest gainer in 'B' group. On the BSE, 15773 shares were traded on the counter so far as against the average daily volumes of 1713 shares in the past one month. BF Utilities Ltd soared 14.98% to Rs 665. The stock was the third biggest gainer in 'B' group. On the BSE, 1.44 lakh shares were traded on the counter so far as against the average daily volumes of 6264 shares in the past one month. BCL Industries Ltd advanced 13.77% to Rs 38.84. The stock was the fourth biggest gainer in 'B' group. On the BSE, 8.87 lakh shares were traded on the counter so far as against the average daily volumes of 86623 shares in the past one month. Indian Hume Pipe Company Ltd added 12.20% to Rs 412.05. The stock was the fifth biggest gainer in 'B' group. On the BSE, 1.01 lakh shares were traded on the counter so far as against the average daily volumes of 12574 shares in the past one month. Powered by Capital Market - Live

Hester Biosciences announced that the 39th Annual General Meeting(AGM) of the company will be held on 21 July 2026.

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 15 May 2026, inter alia, have recommended the final dividend of Rs 11 per equity Share (i.e. 110%) , subject to the approval of the shareholders.

Net profit of Hester Biosciences rose 1138.76% to Rs 15.98 crore in the quarter ended March 2026 as against Rs 1.29 crore during the previous quarter ended March 2025. Sales rose 22.19% to Rs 100.11 crore in the quarter ended March 2026 as against Rs 81.93 crore during the previous quarter ended March 2025. For the full year,net profit rose 102.40% to Rs 55.64 crore in the year ended March 2026 as against Rs 27.49 crore during the previous year ended March 2025. Sales rose 6.91% to Rs 332.60 crore in the year ended March 2026 as against Rs 311.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales100.1181.93 22 332.60311.10 7 OPM %34.2923.41 -26.0619.63 - PBDT28.067.92 254 91.7856.37 63 PBT22.153.75 491 72.9039.57 84 NP15.981.29 1139 55.6427.49 102 Powered by Capital Market - Live

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 15 May 2026.

The company's currently holds around 54.81% stake in Texas Lifesciences. Texas Lifesciences had recorded a turnover of Rs 28.59 crore and its net worth was Rs 13.41 crore in FY2024-25. Offering details of this transaction, the company stated that the 43.81% shareholding of Hester will be transferred to Ticop Life, an entity affiliated to the existing promoter shareholders of TLPL. Hester will continue to do business with TLPL and maintain an 11% equity stake in the company. The company expects to conclude this transaction within a period of three months from the date of this agreement. It will receive a consideration of Rs 9.2 crore as a part of this transaction. Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India. The company had reported 24.79% fall in consolidated net profit to Rs 8.77 crore despite a 22.46% increase in revenue to Rs 77.42 crore in Q3 FY26 as compared with Q3 FY25. The scrip fell 0.17% to currently trade at Rs 1450.00 on the BSE. Powered by Capital Market - Live